Ring-opened aminothienopyridazines as novel tau aggregation inhibitors

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Drug Discovery

Background:

• Tau protein aggregation is a hallmark of neurodegenerative diseases like Alzheimer's.
• Aminothienopyridazines (ATPZs) have shown promise as tau aggregation inhibitors in vitro.
• Understanding structure-activity relationships is crucial for developing effective therapeutics.

Purpose of the Study:

• To investigate the importance of specific structural features in ATPZs for tau aggregation inhibition.
• To synthesize and evaluate ring-opened analogues of ATPZs.
• To identify simpler scaffolds with retained inhibitory activity.

Main Methods:

• Chemical synthesis of novel ring-opened ATPZ analogues.
• In vitro evaluation of the inhibitory activity of synthesized compounds against tau protein aggregation.
• Assessment of activity independent of tau oxidation states.

Main Results:

• Ring-opened ATPZ analogues were successfully synthesized.
• Preliminary data indicates that these ring-opened structures retain tau aggregation inhibitory activity.
• The inhibitory activity appears to be independent of tau oxidation.

Conclusions:

• Structural modifications, including ring-opening, can yield active tau aggregation inhibitors.
• Simpler scaffolds derived from ATPZs may be viable for further optimization.
• This study provides a foundation for developing new therapeutic agents targeting tauopathies.